Gestational Diabetes Long-term therapeutic considerations

Reclassification of maternal glycemic status should be performed at least 6 weeks after delivery and according to the guidelines of the “Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus”. 

Text continued below

If glucose levels are normal post-partum, reassessment of glycemia should be undertaken at a minimum of 3-year intervals. Women with IFG or IGT in the postpartum period should be tested for diabetes annually; these patients should receive intensive MNT and should be placed on an individualized exercise program because of their very high risk for development of diabetes. All patients with prior GDM should be educated regarding lifestyle modifications that lessen insulin resistance, including maintenance of normal body weight through MNT and physical activity. Medications that worsen insulin resistance (e.g., glucocorticoids, Nicotinic Acid) should be avoided if possible. Patients should be advised to seek medical attention if they develop symptoms suggestive of hyperglycemia. Education should also include the need for family planning to assure optimal glycemic regulation from the start of any subsequent pregnancy. Low-dose estrogen-progestogen oral contraceptives may be used in women with prior histories of GDM, as long as no medical contraindications exist.

Therapeutic strategies during pregnancy

Monitoring


  • Maternal metabolic surveillance should be directed at detecting hyperglycemia severe enough to increase risks to the fetus. Daily self-monitoring of blood glucose (SMBG) appears to be superior to intermittent office monitoring of plasma glucose. For women treated with insulin, limited evidence indicates that postprandial monitoring is superior to preprandial monitoring. However, the success of either approach depends on the glycemic targets that are set and achieved.
  • Urine glucose monitoring is not useful in GDM. Urine ketone monitoring may be useful in detecting insufficient caloric or carbohydrate intake in women treated with calorie restriction.
  • Maternal surveillance should include blood pressure and urine protein monitoring to detect hypertensive disorders.
  • Increased surveillance for pregnancies at risk for fetal demise is appropriate, particularly when fasting glucose levels exceed 105 mg/dl (5.8 mmol/l) or pregnancy progresses past term. The initiation, frequency, and specific techniques used to assess fetal well-being will depend on the cumulative risk the fetus bears from GDM and any other medical/obstetric conditions present.
  • Assessment for asymmetric fetal growth by ultrasonography, particularly in early third trimester, may aid in identifying fetuses that can benefit from maternal insulin therapy (see below).

Management

  • All women with GDM should receive nutritional counseling, by a registered dietitian when possible, consistent with the recommendations by the American Diabetes Association. Individualization of medical nutrition therapy (MNT) depending on maternal weight and height is recommended. MNT should include the provision of adequate calories and nutrients to meet the needs of pregnancy and should be consistent with the maternal blood glucose goals that have been established. Noncaloric sweeteners may be used in moderation.
  • For obese women (BMI >30 kg/m2), a 30–33% calorie restriction (to ~25 kcal/kg actual weight per day) has been shown to reduce hyperglycemia and plasma triglycerides with no increase in ketonuria (2). Restriction of carbohydrates to 35–40% of calories has been shown to decrease maternal glucose levels and improve maternal and fetal outcomes (3).
  • Insulin is the pharmacologic therapy that has most consistently been shown to reduce fetal morbidities when added to MNT. Selection of pregnancies for insulin therapy can be based on measures of maternal glycemia with or with-out assessment of fetal growth characteristics. When maternal glucose levels are used, insulin therapy is recommended when MNT fails to maintain self-monitored glucose at the following levels: Fasting whole blood glucose <=95 mg/dl (5.3 mmol/l) Fasting plasma glucose <=105 mg/dl (5.8 mmol/l) or 1-h postprandial whole blood glucose <=140 mg/dl (7.8 mmol/l) 1-h postprandial plasma glucose <=155 mg/dl (8.6 mmol/l) or 2-h postprandial whole blood glucose <=120 mg/dl (6.7 mmol/l) 2-h postprandial plasma glucose <=130 mg/dl (7.2 mmol/l)
  • Measurement of the fetal abdominal circumference early in the third trimester can identify a large subset of infants with no excess risk of macrosomia in the absence of maternal insulin therapy. This approach has been tested primarily in pregnancies with maternal fasting serum glucose levels <105 mg/dl (5.8 mmol/l).
  • Human insulin should be used when insulin is prescribed, and SMBG should guide the doses and timing of the insulin regimen. The use of insulin analogs has not been adequately tested in GDM.
  • Oral glucose-lowering agents have generally not been recommended during pregnancy. However, one randomized, unblinded clinical trial compared the use of insulin and glyburide in women with GDM who were not able to meet glycemic goals on MNT (4). Treatment with either agent resulted in similar perinatal outcomes. All patients were beyond the first trimester of pregnancy at the initiation of therapy. Glyburide is not FDA approved for the treatment of gestational diabetes and further studies are needed in a larger patient population to establish its safety.
  • Programs of moderate physical exercise have been shown to lower maternal glucose concentrations in women with GDM. Although the impact of exercise on neonatal complications awaits rigorous clinical trials, the beneficial glucose lowering effects warrant a recommendation that women without medical or obstetrical contraindications be encouraged to start or continue a program of moderate exercise as a part of treatment for GDM.
  • GDM is not of itself an indication for cesarean delivery or for delivery before 38 completed weeks gestation. Prolongation of gestation past 38 weeks increases the risk of fetal macrosomia without reducing cesarean rates, so that delivery during the 38th week is recommended unless obstetric considerations dictate otherwise.
  • Breast-feeding, as always, should be encouraged in women with GDM.

Nov 29, 06 • Gestational diabetes •